Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued on Friday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of NASDAQ:EGRX opened at $1.49 on Friday. Eagle Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $6.37. The business has a 50 day simple moving average of $1.05 and a two-hundred day simple moving average of $1.30.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of EGRX. RBF Capital LLC boosted its holdings in shares of Eagle Pharmaceuticals by 11.7% in the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after purchasing an additional 14,991 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Eagle Pharmaceuticals in the third quarter valued at approximately $453,000. DGS Capital Management LLC boosted its holdings in shares of Eagle Pharmaceuticals by 44.9% in the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after purchasing an additional 22,239 shares during the period. Finally, Jane Street Group LLC purchased a new stake in shares of Eagle Pharmaceuticals in the third quarter valued at approximately $96,000. Hedge funds and other institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.